Global DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026

List of Tables

Global DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026 Report Findings & Highlights:

First DNA Cancer Vaccine commercial Approval Expected By 2030
DNA Cancer Vaccines In Clinical Trials: > 20 Vaccines
Global DNA Cancer Vaccines Clinical Trial Insight By Company, Indication & Phase
Insight On DNA Cancer Vaccine Development Technology Platforms: >10 Platforms
Comparison With Other Cancer Immunotherapies
DNA Cancer Vaccines Recent Innovations
Competitive Landscape

Need For Cancer DNA Vaccines and Why This Report

The global impact of cancer remains profound, with millions of new cases and high mortality, particularly in advanced and hard to treat cancers. Although immunotherapies such as checkpoint inhibitors have transformed the cancer therapeutic landscape, they are not effective across the board. DNA vaccines present a new era of cancer therapy by providing tumor specific antigens encoded in plasmid DNA that activate the body's immune response to detect and target cancer cells. They are attractive due to their safety, stability, fast production, and the ability to be tailored or personalized.

This report is timely and much needed, providing stakeholders, ranging from researchers to investors, clear insight into the current state of cancer DNA vaccine development. It summarizes the existing clinical activity, nascent technologies, key companies, and strategic partnerships. As the field rapidly advances, the report delivers a well-curated, recent snapshot of where innovation is headed, why it is important, and how it might transform the future of cancer care.

Cancer DNA Vaccines Clinical Trials Insight Covered In Report

DNA vaccines are currently in clinical development, many of them moving into mid to late stage testing. One of the most advanced, Inovio Pharmaceuticals' HPV-associated cervical cancer candidate based on plasmid DNA administered using electroporation, shows how DNA vaccines can be used against virus-driven cancers. IMUNON's IMNN-001, being tested for ovarian cancer, combines DNA with IL-12 immunostimulation and chemotherapy and is reporting promising survival trends in Phase II.

This overview calls attention to the scale of global clinical trials, such as melanoma, lung, and prostate cancer, and offers insights into trial phases, delivery strategies, combination regimens, and immunological endpoints. Data provided serves to place into context which strategies are most proximal to clinical translation and how future efforts will look like.

Technology Platforms, Partnerships & Agreements

Platform and delivery advancements are the cornerstone of DNA vaccine technology. Electroporation is still a dominant way to deliver improved uptake, but other systems are picking up steam. NEC Bio Therapeutics, for example, is testing an oral, bacteria-delivery based DNA vaccine that uses machine learning to identify patient-specific tumor mutations for targeting. IMUNON's PlaCCine(R) platform, initially designed for infectious disease, is being repurposed for oncology because it has the ability to deliver multiple antigens with improved stability.

The report outlines major collaborations, including Immuno Cure and PharmaJet's partnership, which employs a needle-free intradermal injection system to enhance patient compliance and immune response. These collaborations are part of a larger trend of merging proprietary DNA constructs with third-party delivery systems for faster development and scale-up.

Leading Companies Active In RandD On Cancer DNA Vaccines

A number of companies are at the forefront in this field. Inovio, Scancell, IMUNON, and NEC Bio are all committing significant resources to R&D and clinical trials. Scancell's intradermally delivered iSCIB1+ melanoma vaccine, administered in combination with checkpoint inhibitors, is recruiting patients on the UK's NHS Cancer Vaccine Launch Pad. The report outlines these companies and others, providing an overview of their pipelines, therapeutic areas of interest, delivery mechanisms, and strategic partnerships.

Report Indicating Future Development Of Cancer DNA Vaccines

Looking ahead, the report points out significant opportunities fueling the next generation of innovation. These are the application of minicircle DNA (mcDNA) for cleaner, more efficient gene expression, the development of DNA origami-based platforms such as DoriVac for targeted immune stimulation, and gene editing tools including CRISPR to optimize vaccine constructs. Furthermore, preventive approaches such as LungVax, a DNA vaccine in development in the UK for patients at high risk of lung cancer, point to an even wider use of DNA vaccines beyond therapy.

As more clinical evidence mounts, improved delivery devices, and compatibility with current therapies, DNA cancer vaccines will be a central column of oncology treatment in the years to come.

1. Overview Of DNA Cancer Vaccines

1.1 What Are DNA Cancer Vaccines?
1.2 History & Development Timeline
1.3 Comparison With Other Cancer Immunotherapies
1.4 Advantages & Limitations

2. DNA Cancer Vaccines - Mechanism of Action

2.1 How DNA Vaccines Work
2.2 Antigen Selection & Delivery
2.3 Role Of Vectors & Adjuvants
2.4 Immune Activation Pathways

3. Global DNA Cancer Vaccines - Recent Innovations

4. Global DNA Cancer Vaccines Market Overview

4.1 Current Market Scenario
4.2 Future Opportunity Outlook

5. DNA Cancer Vaccine Development Trends By Indication

5.1 Prostate Cancer
5.2 Cervical Cancer
5.3 Lung Cancer
5.4 Melanoma
5.5 Breast Cancer

6. DNA Cancer Vaccine Development Technology Platforms

7. Global DNA Cancer Vaccines Clinical Trials Overview

7.1 By Company
7.2 By Indication
7.3 By Phase

8. Global DNA Cancer Vaccines Clinical Trial Insight By Company, Indication & Phase

8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase II
8.5 Phase III

9. Global DNA Cancer Vaccines Market Dynamics

9.1 Growth Drivers & Opportunities
9.2 Market Restraints & Solutions

10. Competitive Landscape

10.1 4basebio
10.2 Aston Sci
10.3 Genexine
10.4 Evaxion
10.5 Immunomic Therapeutics
10.6 INOVIO
10.7 Madison Vaccines
10.8 Nykode Therapeutics
10.9 PapiVax Biotech
10.10 Takis

List of Figures

Figure 1-1: DNA Cancer Vaccines - Mechanism
Figure 1-2: DNA Cancer Vaccine - Milestones
Figure 1-3: DNA Cancer Vaccines - Safety Profile
Figure 1-4: DNA Vaccines vs. Other Immunotherapies - Durability Of Response
Figure 1-5: DNA Vaccine Delivery Methods
Figure 1-6: DNA Vaccine Immunogenicity - Challenges
Figure 2-1: DNA Vaccine Immune Response
Figure 2-2: DNA Vaccine - Antigen Presentation To Immune System
Figure 2-3: DNA Cancer Vaccine - Final Immune Response
Figure 2-4: Types Of Tumor Antigens
Figure 2-5: Challenges with Antigen Selection
Figure 2-6: Plasmid Vectors
Figure 2-7: Bacterial Vectors
Figure 2-8: Viral Vectors
Figure 2-9: Adjuvants In DNA Cancer Vaccines
Figure 2-10: New Developments In Adjuvants
Figure 2-11: DNA Sensors & Their Roles in Immune Activation
Figure 3-1: DoriVac DNA Vaccine Mechanism
Figure 3-2: μEPO System - Key Features & Breakthroughs
Figure 3-3: Neomatrix Biotech: Revolutionizing Personalized Cancer Immunotherapy
Figure 4-1: Global DNA Cancer Vaccines Market - Future Opportunities
Figure 5-1: UW18037 Phase 2 (NCT04090528) Study - Initiation & Completion Year
Figure 5-2: UW25025 Phase 1 (NCT07090148) Study - Initiation & Completion Year
Figure 5-3: UW18008 Phase 2 (NCT03600350) Study - Initiation & Completion Year
Figure 5-4: J23105sIRB Phase 1 (NCT06315257) Study - Initiation & Completion Year
Figure 5-5: J1955 Phase 2 (NCT04131413) Study - Initiation & Completion Year
Figure 5-6: BB IND 18340 Phase 1 (NCT03913117) Study - Initiation & Completion Year
Figure 5-7: NEWISH-HPV-101 Phase 1 (NCT06276101) Study - Initiation & Completion Year
Figure 5-8: 202104143 Phase 2 (NCT04397003) Study - Initiation & Completion Year
Figure 5-9: NCI-2021-14159 Phase 2 (NCT05242965) Study - Initiation & Completion Year
Figure 5-10: SCOPE Phase 2 (NCT04079166) Study - Initiation & Completion Year
Figure 5-11: SCOPE Phase 2 (NCT04079166) Study - Initiation & Completion Year
Figure 5-12: SCOPE Phase 2 (NCT04079166) Study - Initiation & Completion Year
Figure 5-13: W81XWH-15-1-0101 Phase 1 (NCT02204098) Study - Initiation & Completion Year
Figure 5-14: NCI-2014-01070 Phase 1 (NCT02157051) Study - Initiation & Completion Year
Figure 5-15: NCI-2025-04692 Phase 2 (NCT07112053) Study - Initiation & Completion Year
Figure 5-16: NCI-2020-01662 Phase 2 (NCT04329065) Study - Initiation & Completion Year
Figure 5-17: NECVAX-NEO1-05-DE Phase 1/2 (NCT06631092) Study - Initiation & Completion Year
Figure 6-1: Enzymatic manufacturing process
Figure 6-2: Genexine - DNA Vaccine Platform
Figure 6-3: MVI Technology - DNA Plasmid Mechanism Of Action
Figure 6-4: Nykode - Protein Format
Figure 6-5: Nykode Therapeutics - DNA Vaccine Mechanism Of Action
Figure 6-6: DNA Medicines Technology - INOVIO
Figure 6-7: UNITE - Mode Of Action
Figure 6-8: GT-EPIC Platform - Process
Figure 6-9: LineaDNA - Production Process
Figure 6-10: GeneOne DNA Plasmid Technology - Principle
Figure 6-11: Fusogenix - FAST Protein Structure
Figure 6-12: PLV Technology
Figure 6-13: PLV Technology - Delivery Mechanism
Figure 7-1: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Company , 2025 -2026
Figure 7-2: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Indication (Numbers), 2025 -2026
Figure 7-3: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Phase (Numbers), 2025 - 2026
Figure 9-1: Global DNA Cancer Vaccines Market - Drivers & Opportunities
Figure 9-2: Global DNA Cancer Vaccines Market - Restraints & Solutions

List of Tables

Table 1-1: DNA Cancer Vaccines - Delivery Methods
Table 1-2: DNA Vaccine Platforms - Comparison
Table 1-3: DNA Cancer Vaccines - Comparison With Other Immunotherapies
Table 1-4: DNA Cancer Vaccines vs. mRNA Vaccines
Table 1-5: DNA Cancer Vaccines - Scalability & Manufacturing
Table 1-6: DNA Cancer Vaccines - Advantages
Table 6-1: LineaDNA - At A Glace

Global DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026

Description

Table of Contents

List of Tables

Table of Contents

1. Overview Of DNA Cancer Vaccines

2. DNA Cancer Vaccines - Mechanism of Action

3. Global DNA Cancer Vaccines - Recent Innovations

4. Global DNA Cancer Vaccines Market Overview

5. DNA Cancer Vaccine Development Trends By Indication

6. DNA Cancer Vaccine Development Technology Platforms

7. Global DNA Cancer Vaccines Clinical Trials Overview

8. Global DNA Cancer Vaccines Clinical Trial Insight By Company, Indication & Phase

9. Global DNA Cancer Vaccines Market Dynamics

10. Competitive Landscape

List of Figures

List of Tables